BioMarin Pharma (BMRN) Tops Q3 EPS by 5c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $63.94 -1.75%
EPS Growth %: +1,008.3%
Financial Fact:
NET INCOME (LOSS): -42.8M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +1,008.3%
Financial Fact:
NET INCOME (LOSS): -42.8M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 GAAP EPS of ($0.07), $0.05 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $334.1 million versus the consensus estimate of $349.59 million.
GUIDANCE:
BioMarin Pharma sees FY2017 revenue of $1.29-1.32 billion, versus the consensus of $1.31 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $97 at BMO Capital
- Amneal gets FDA approval for lanreotide injection, launches immediately
- Redburn upgrades Southwest, stays bullish on Delta and United
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
